393 related articles for article (PubMed ID: 22100015)
21. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
22. Kawasaki disease in Sicily: clinical description and markers of disease severity.
Maggio MC; Corsello G; Prinzi E; Cimaz R
Ital J Pediatr; 2016 Nov; 42(1):92. PubMed ID: 27806720
[TBL] [Abstract][Full Text] [Related]
23. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
[TBL] [Abstract][Full Text] [Related]
25. Kawasaki disease: Medical therapies.
Newburger JW
Congenit Heart Dis; 2017 Sep; 12(5):641-643. PubMed ID: 28580631
[TBL] [Abstract][Full Text] [Related]
26. [Kawasaki disease: what you need to know].
Bajolle F; Laux D
Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712
[TBL] [Abstract][Full Text] [Related]
27. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
Chen S; Dong Y; Kiuchi MG; Wang J; Li R; Ling Z; Zhou T; Wang Z; Martinek M; Pürerfellner H; Liu S; Krucoff MW
JAMA Pediatr; 2016 Dec; 170(12):1156-1163. PubMed ID: 27749951
[TBL] [Abstract][Full Text] [Related]
28. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
[TBL] [Abstract][Full Text] [Related]
29. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease.
Chang LS; Lo MH; Li SC; Yang MY; Hsieh KS; Kuo HC
Oncotarget; 2017 Jan; 8(2):2044-2052. PubMed ID: 27893416
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease.
Tang B; Lo HH; Lei C; U KI; Hsiao WW; Guo X; Bai J; Wong VK; Law BY
Phytomedicine; 2020 Apr; 70():153208. PubMed ID: 32283413
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
Wang L; He M; Wang W; Li S; Zhao G
Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial.
Kuo HC; Guo MM; Lo MH; Hsieh KS; Huang YH
BMC Pediatr; 2018 Jun; 18(1):200. PubMed ID: 29933749
[TBL] [Abstract][Full Text] [Related]
34. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.
Zhu BH; Lv HT; Sun L; Zhang JM; Cao L; Jia HL; Yan WH; Shen YP
Eur J Pediatr; 2012 Mar; 171(3):571-8. PubMed ID: 22057683
[TBL] [Abstract][Full Text] [Related]
35. Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study.
Inamo Y; Saito K; Hasegawa M; Hayashi R; Nakamura T; Abe O; Ishikawa T; Yoshino Y; Hashimoto K; Fuchigami T
BMC Pediatr; 2014 Jan; 14():27. PubMed ID: 24479564
[TBL] [Abstract][Full Text] [Related]
36. Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial.
Lin SY; He L; Xie LP; Wang Y; Lin YX; Cao YY; Yan WL; Liu F; Huang GY
Trials; 2021 Dec; 22(1):898. PubMed ID: 34895290
[TBL] [Abstract][Full Text] [Related]
37. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
Amano Y; Akazawa Y; Yasuda J; Yoshino K; Kojima K; Kobayashi N; Matsuzaki S; Nagasaki M; Kawai Y; Minegishi N; Ishida N; Motoki N; Hachiya A; Nakazawa Y; Yamamoto M; Koike K; Takeshita T
Pediatr Rheumatol Online J; 2019 Jul; 17(1):34. PubMed ID: 31269967
[TBL] [Abstract][Full Text] [Related]
38. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
Samadli S; Liu FF; Mammadov G; Wang JJ; Liu HH; Wu YF; Luo HH; Wu Y; Chen WX; Zhang DD; Wei W; Hu P
Pediatr Rheumatol Online J; 2019 Jul; 17(1):53. PubMed ID: 31366406
[TBL] [Abstract][Full Text] [Related]
39. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease.
Hu P; Jiang GM; Wu Y; Huang BY; Liu SY; Zhang DD; Xu Y; Wu YF; Xia X; Wei W; Hu B
Clin Chim Acta; 2017 Aug; 471():76-80. PubMed ID: 28526535
[TBL] [Abstract][Full Text] [Related]
40. [Immunoglobulin therapy].
Ogata S; Ishii M
Nihon Rinsho; 2014 Sep; 72(9):1617-22. PubMed ID: 25518412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
